Atoltivimab/maftivimab/odesivimab
Atoltivimab/Maftivimab/Odesivimab
Atoltivimab/Maftivimab/Odesivimab (pronunciation: a-tol-ti-vi-mab/maf-ti-vi-mab/o-desi-vi-mab) is a combination of three monoclonal antibodies that is used in the treatment of Zaire ebolavirus infection.
Etymology
The names of these drugs follow the World Health Organization's guidelines for the International Nonproprietary Names (INN) of monoclonal antibodies. The suffix "-mab" is used for monoclonal antibodies, "vi" denotes viral targets, and the prefixes are randomly assigned.
Usage
Atoltivimab/Maftivimab/Odesivimab is used together in a single infusion for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Related Terms
- Monoclonal antibodies: Antibodies that are made by identical immune cells that are all clones of a unique parent cell.
- Zaire ebolavirus: One of six known species within the genus Ebolavirus. Zaire ebolavirus is the most dangerous of the known EVD-causing viruses, and is responsible for the largest number of outbreaks.
See Also
External links
- Medical encyclopedia article on Atoltivimab/maftivimab/odesivimab
- Wikipedia's article - Atoltivimab/maftivimab/odesivimab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski